California Public Employees Retirement System Has $1,872,000 Position in Genomic Health Inc. (GHDX)
California Public Employees Retirement System reduced its position in shares of Genomic Health Inc. (NASDAQ:GHDX) by 21.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 72,300 shares of the company’s stock after selling 20,000 shares during the period. California Public Employees Retirement System owned about 0.22% of Genomic Health worth $1,872,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the stock. Emerald Acquisition Ltd. acquired a new stake in Genomic Health during the second quarter worth $1,983,000. Swiss National Bank boosted its stake in Genomic Health by 2.3% in the second quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $808,000 after buying an additional 700 shares during the last quarter. Columbus Circle Investors acquired a new stake in Genomic Health during the second quarter worth $1,376,000. California State Teachers Retirement System boosted its stake in Genomic Health by 4.0% in the second quarter. California State Teachers Retirement System now owns 39,167 shares of the company’s stock worth $1,014,000 after buying an additional 1,510 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Genomic Health by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 88,963 shares of the company’s stock worth $2,304,000 after buying an additional 2,315 shares during the last quarter. 88.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of Genomic Health Inc. (NASDAQ:GHDX) traded down 0.03% during trading on Friday, hitting $30.19. 59,255 shares of the stock were exchanged. The firm has a 50 day moving average price of $27.84 and a 200 day moving average price of $27.09. Genomic Health Inc. has a 52 week low of $20.05 and a 52 week high of $35.79. The firm’s market capitalization is $1.01 billion.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The business earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. During the same quarter in the previous year, the company earned ($0.29) EPS. The business’s revenue was up 16.1% on a year-over-year basis. Analysts forecast that Genomic Health Inc. will post ($0.47) EPS for the current fiscal year.
Several analysts have weighed in on GHDX shares. Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Tuesday. Jefferies Group upped their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a research note on Friday, August 5th. Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Genomic Health currently has a consensus rating of “Hold” and a consensus price target of $32.50.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $28.87, for a total value of $144,350.00. Following the transaction, the chief operating officer now directly owns 40,426 shares of the company’s stock, valued at approximately $1,167,098.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James J. Vaughn sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $28.74, for a total transaction of $86,220.00. The disclosure for this sale can be found here. 47.00% of the stock is currently owned by company insiders.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.